What will the FDA's decision be on Gedatolisib by Celcuity Inc. in July 2026
Leader sits at 76% across 4 bound outcomes, runner-up at 9%. This is a winner-take-all market — the headline is the leader’s price, not an arithmetic mean.
Leader probability
Full Approval
Outcomes
4
winner-take-all
Runner-up
9¢
Denied (CRL Issued)
Spread
67pp
dominant leader
24h volume
$23
thin orderbook
Closes
Aug 1, 2026
36 days
Venue
Kalshi
4 bound
30-day trend
Bracket family
How the bracket ladder is priced.
Each row is one outcome on the venue. Sorted by 24h volume — the heaviest book is at the top.
Cluster 1
What will the FDA's decision be on Gedatolisib by Celcuity Inc. in July 2026
What will the FDA's decision be on Gedatolisib by Celcuity Inc. in July 2026?: Full Approval
KXGEDATOLISIB-26-FA
What will the FDA's decision be on Gedatolisib by Celcuity Inc. in July 2026?: No Decision
KXGEDATOLISIB-26-ND
What will the FDA's decision be on Gedatolisib by Celcuity Inc. in July 2026?: Denied (CRL Issued)
KXGEDATOLISIB-26-DN
What will the FDA's decision be on Gedatolisib by Celcuity Inc. in July 2026?: Conditional / Accelerated Approval
KXGEDATOLISIB-26-CA
Analysis
Markets are pricing an approximately 75% likelihood that the FDA will grant full approval for Gedatolisib (a Celcuity Inc. oncology candidate) by the end of July 2026. This probability reflects the drug's regulatory progress toward a potential approval decision within the specified timeframe. The current level is driven by the timing of the FDA review cycle and the therapeutic area's historical approval rates for similar agents. The primary catalyst would be the formal FDA decision, which typically follows completion of the agency's standard or priority review period. Approval odds would increase if recent clinical data demonstrate efficacy and safety improvements over existing treatments, while they would decline if the FDA issues a complete response letter requesting additional data, or if the decision timeline extends beyond July.
- ›FDA review timeline completion: whether the agency's decision date falls within July 2026 versus extending into later months
- ›Recent clinical trial outcomes for Gedatolisib: efficacy and safety profile relative to competitor drugs in the same indication
- ›Celcuity's regulatory communication history: any preliminary feedback or deficiency letters from the FDA before July
- ›Historical approval rates for oncology candidates in this drug class and indication
- ›Competitive landscape: whether other similar agents recently gained approval, which could influence FDA precedent and decision momentum
What moved the line
- Jun 20Full Approval↓3pp76→73¢ · Kalshi
- Jun 21No Decision↓3pp6→3¢ · Kalshi
Recently closed in general
- Will Claire Valdez be victorious in the NY-07 Democratic primary AND Brad Lander be victorious in the NY-10 Democratic primary AND Darializa Avila Chevalier be defeated in the NY-13 Democratic primary for Sep 2026last 69% · 1d
- Will Darializa Avila Chevalier be victorious in the NY-13 Democratic primary AND Alex Bores be defeated in the NY-12 Democratic primary for Sep 2026last 37% · 2d
- Who will win the 2026 D.C. Democratic Mayoral Primarylast 97% · 7d
- Louisiana Democratic Senate Primary Winnerlast 89% · 7d
- Will Databricks' valuation hit __ by December 31?: ↑$180Blast 94% · 7d
These markets stopped trading. Last odds and any captured outcome are shown above — full settlement detail lives at the venue.
More like this
Adjacent prediction questions.
In general
How we compute these odds
SimpleFunctions aggregates live prediction-market contracts from Kalshi and Polymarket. Each slug groups contracts that resolve on the same underlying event, identified by venue event_id.
For binary slugs, the headline probability is the liquidity-weighted mid-price across all bound contracts. For multi-outcome slugs (e.g. elections with 3+ candidates), the headline is the leader’s price; we never arithmetically average disjoint outcomes — that would produce a number with no real-world meaning.
Snapshots refresh every 5 minutes during market hours; daily aggregates are computed at 04:00 UTC. The 30-day sparkline is drawn from per-ticker daily means stored in market_indicator_daily; 24h delta and movement events are derived from the same source.
Last updated on this page: just now.